Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite a steady downpour that making the Pharmalot campus grounds particularly soggy. Nonetheless, our spirits are sunny. Once again, we will offer a gentle reminder from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So after you tug on the ribbon, you can peruse a few items of interest we have assembled for you. Hope you have a smashing day …

AbbVie (ABBV) will pay $63 billion to buy Allergan (AGN), the latest megamerger between two pharma giants seeking new ways to grow, STAT reports. For AbbVie, the acquisition may ease investor concerns about long-term growth, since patents expire in a few years on its franchise product, the Humira rheumatoid arthritis treatment. Allergan sells a portfolio of aesthetic drugs, notably Botox, a $3.6 billion seller, but has struggled with pressure from investor over its own growth plans amid a failed move to extend patent life for an eye treatment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy